[Oral effectiveness of the calcium-antagonist Ro 11-1781 (Tiapamil) in supraventricular and ventricular extrasystoles (author's transl)].
The effectiveness of the calcium-antagonist Ro 11-1781 (Tiapamil) was investigated in 23 patients with extrasystoles of different origin using continuous ECG recordings. Two 24-hour ECG recordings were registered without antiarrhythmic medication, one of these as a placebo period, and 3 during oral application of 3 x 200 mg/day Ro 11-1781, if the state of the health of the patients allowed it. No positive effects of Ro 11-1781 in supraventricular and ventricular extrasystoles were demonstrable, supported by 8 premature terminations of the study. The missing antiarrhythmic effectiveness of Ro 11-1781 corresponds to Verapamil in oral application.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011437:Propylamines / Q000627:therapeutic use*; D013976:Tiapamil Hydrochloride
D011437:Propylamines; D013976:Tiapamil Hydrochloride
Orale Wirksamkeit des Calciumantagonisten Ro 11-1781 (Tiapamil) bei supraventrikulären und ventrikulären Extrasystolen.